Torup L - Search Results

1

Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.

Mann K, Torup L, Sørensen P, Gual A, Swift R, Walker B, van den Brink W. Mann K, et al. Among authors: torup l. Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949. doi: 10.1016/j.euroneuro.2016.10.008. Epub 2016 Nov 12. Eur Neuropsychopharmacol. 2016. PMID: 27842940 Review.

2

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Mann K, Bladström A, Torup L, Gual A, van den Brink W. Mann K, et al. Among authors: torup l. Biol Psychiatry. 2013 Apr 15;73(8):706-13. doi: 10.1016/j.biopsych.2012.10.020. Epub 2012 Dec 11. Biol Psychiatry. 2013. PMID: 23237314 Clinical Trial.

3

A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group. Gual A, et al. Among authors: torup l. Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006. Epub 2013 Apr 3. Eur Neuropsychopharmacol. 2013. PMID: 23562264 Clinical Trial.

4

Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.

van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K. van den Brink W, et al. Among authors: torup l. Alcohol Alcohol. 2013 Sep-Oct;48(5):570-8. doi: 10.1093/alcalc/agt061. Epub 2013 Jul 19. Alcohol Alcohol. 2013. PMID: 23873853 Free PMC article. Clinical Trial.

5

Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.

van den Brink W, Sørensen P, Torup L, Mann K, Gual A; SENSE Study Group. van den Brink W, et al. Among authors: torup l. J Psychopharmacol. 2014 Aug;28(8):733-44. doi: 10.1177/0269881114527362. Epub 2014 Mar 26. J Psychopharmacol. 2014. PMID: 24671340 Clinical Trial.

6

Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.

Falk DE, Litten RZ, Anton RF, Kranzler HR, Johnson BA; Active Workgroup. Falk DE, et al. J Stud Alcohol Drugs. 2014 Mar;75(2):335-46. doi: 10.15288/jsad.2014.75.335. J Stud Alcohol Drugs. 2014. PMID: 24650828 Free PMC article. Clinical Trial.

7

What happens when people discontinue taking medications? Lessons from COMBINE.

Stout RL, Braciszewski JM, Subbaraman MS, Kranzler HR, O'Malley SS, Falk D; ACTIVE group. Stout RL, et al. Addiction. 2014 Dec;109(12):2044-52. doi: 10.1111/add.12700. Epub 2014 Sep 12. Addiction. 2014. PMID: 25098969 Free PMC article. Clinical Trial.

8

Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.

Aubin HJ, Reimer J, Nutt DJ, Bladström A, Torup L, François C, Chick J. Aubin HJ, et al. Among authors: torup l. Eur Addict Res. 2015;21(3):160-168. doi: 10.1159/000371547. Epub 2015 Mar 31. Eur Addict Res. 2015. PMID: 25832297 Free article. Clinical Trial.

9

Neuroprotective effect of 8-OH-DPAT in global cerebral ischemia assessed by stereological cell counting.

Torup L, Møller A, Sager TN, Diemer NH. Torup L, et al. Eur J Pharmacol. 2000 Apr 28;395(2):137-41. doi: 10.1016/s0014-2999(00)00175-8. Eur J Pharmacol. 2000. PMID: 10794819

10

Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia.

Torup L, Borsdal J, Sager T. Torup L, et al. Neurosci Lett. 2003 Nov 20;351(3):173-6. doi: 10.1016/j.neulet.2003.08.008. Neurosci Lett. 2003. PMID: 14623134

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters